Bayer’s Pipeline Progress Confronts US Tariff Threats and Legal Overhangs
Published on 06/19/2026 at 21:16 | Redaktion boerse-global.de
A drug candidate with priority review status in three major markets, a $2.45 billion ophthalmology deal, and solid first-quarter numbers — none of that has been enough to shake Bayer’s share price out of its narrow trading range. Instead, the stock remains trapped between a promising pipeline and the twin weight of US tariff threats and unresolved glyphosate litigation.
The most striking development for the pharma division is Asundexian, the stroke prevention asset that has quietly gathered regulatory momentum. The European Medicines Agency launched its approval review in June 2026, while both the Chinese Center of Drug Evaluation and the US Food and Drug Administration have granted priority review designations. That puts the drug on an accelerated path in three of the world’s largest pharmaceutical markets simultaneously. The Phase III OCEANIC-STROKE trial showed that Asundexian reduced the risk of ischemic stroke by 26 percent versus placebo without increasing major bleeding — a profile that addresses a serious unmet need, given that stroke is the second-leading cause of death in Europe according to the EMA.
Bayer bolstered its ophthalmology pipeline on June 17 by closing the acquisition of Perfuse Therapeutics, securing full rights to PER-001, a sustained-release candidate for glaucoma and diabetic retinopathy currently in Phase II. The upfront payment was $300 million, with the total deal value potentially reaching $2.45 billion including milestone payments. It is a long-term bet: the drug is still years from approval, and the upfront cost already reflects the risk.
Operationally, the company is showing resilience. First-quarter 2026 revenues rose 4.1 percent on a currency-adjusted basis to €13.4 billion, while EBITDA before special items jumped 9.0 percent to €4.5 billion. Those are hardly the numbers of a business in crisis. Yet the balance sheet tells a different story. Net cash outflows of €2.0 billion in the quarter, largely to settle PCB and glyphosate lawsuits, pushed net financial debt to €32.5 billion as of March 31. Until the total cost of America’s legal assault is clearer, investors remain cautious.
Should investors sell immediately? Or is it worth buying Bayer?
That caution is compounded by a fresh threat from Washington. US Trade Representative Jamieson Greer last Friday launched an official investigation into German pharmaceutical pricing practices, accusing Berlin of keeping drug prices artificially low while American patients bear a disproportionate share of research costs. If the probe finds evidence of unfair trade practices, Bayer and other German pharma groups could face punitive tariffs. Months of bilateral talks have yielded no deal — unlike Britain, which signed a similar pact with the US in April.
Meanwhile, Brussels has thrown a lifeline to Bayer’s agriculture division. The European Parliament voted Thursday to ease rules on gene-edited plants, creating a new category that exempts less invasive modifications from special labelling and lengthy approval procedures. Crucially, patents on such seeds remain permissible. The new rules take effect in mid-2028, giving Crop Science a clear regulatory tailwind.
Analysts are watching the legal calendar closely. UBS’s Matthew Weston maintains a Buy rating with a €52 target, pointing to a recent procedural win in the glyphosate battle — a multibillion-dollar settlement has been referred back to a Missouri court. Berenberg and Jefferies both rate the stock a Hold, with targets of €40.50 and €40 respectively. The next milestone is a July 9 hearing in St. Louis that will determine the fate of the glyphosate settlement and shape the company’s legal trajectory for the foreseeable future.
Bayer at a turning point? This analysis reveals what investors need to know now.
The stock has been drifting. At €37.79 before the trade probe emerged, it has since edged down to around €37.10, still holding above the 200-day moving average of €36.22. On June 17 the share price crossed that line to the upside — a technically positive signal, but not yet a trend reversal. The relative strength index sits at 55.7, indicating neither overbought nor oversold conditions.
Bayer’s narrative is no longer defined solely by glyphosate headlines, but the market remains sceptical. With Asundexian moving toward approval, a strengthened ophthalmology pipeline, and improving agricultural regulation, the underlying business is showing signs of life that the current share price — roughly 24 percent below its February high — may not fully reflect. Still, the convergence of a US trade investigation and a pivotal court date means that any rally will have to contend with one of the most uncertain summers in the company’s recent history.
Ad
Bayer Stock: New Analysis - 19 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
